EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, INSM: Insmed Inc

07 Oct 26 15:59
LAST:

101.7

CHANGE:
 3.50		OPEN:
105.0		HIGH:
105.0		ASK:
25.6		VOLUME:
1.43M
CHG(%):
3.32		PREV:
105.2		LOW:
101.6		BID:
0.7		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
07 Oct 26105.0105.0101.6101.71.43M
06 Oct 26104.0107.9101.3105.23.69M
05 Oct 26105.5108.8101.7103.85.4M
02 Oct 26107.8111.5105.7111.14.14M
01 Oct 26114.7116.2108.5108.62.65M
30 Sep 26115.7116.4113.6114.12.87M
29 Sep 26117.1118.5114.5115.61.67M
28 Sep 26116.8119.3116.3117.71.74M
25 Sep 26121.9122.9115.9117.82.67M
24 Sep 26119.3121.7118.4121.62.23M

PROFILE

Name:Insmed Inc
About:Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Sector:Healthcare
Industry:Biotechnology
Address:700 US Highway 202/206, Bridgewater, NJ, United States, 08807
Website:https://www.insmed.com
CUSIP:457669109
CIK:0001104506
ISIN:US4576693075
FIGI:BBG000BWM5P3
LEI:529900Q55QAG41CCAC11

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-33.43 
Forward P/E:143.42 
PEG Ratio:2.70 
Price to Sales:90.46 
Price to Book:32.02 
Profit Margin:-2.65 
Operating Margin:-1.84 
Return on Assets:-0.28 
Return on Equity:-1.66 
EPS Ratio:-4.12 
Revenue:447.02M 
Shares:218.38M 
Market Cap:22.209B 

TECHNICAL INDICATORS

MA5:106.094.3%
MA10:111.739.9%
MA20:117.3015.3%
MA50:119.7217.7%
MA100:112.5010.6%
MA200:131.8129.6%
RSI14:21.11 
WPR14:-100.00 
MTM14:-18.30
ROC14:-0.15 
ATR:5.14 
Week High:116.4314.5%
Week Low:101.320.4%
Month High:130.8328.6%
Month Low:101.3229.6%
Year High:212.75109.2%
Year Low:90.3912.5%
Volatility:14.83 

RECENT SPLITS

Date Ratio
03 Mar 20111-10
31 Jul 20001-4